Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery; Experience and Short Term Outcomes

Authors

  • Ümit Özdemir Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Gastroenterological Surgery, Eskişehir, Turkey
  • Ahmet Karayiğit Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Surgical Oncology, Eskişehir, Turkey
  • Dursun Burak Özdemir Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Surgical Oncology, Eskişehir, Turkey
  • İhsan Burak Karakaya Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Gastroenterological Surgery
  • Hayrettin Dizen Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Surgical Oncology, Eskişehir
  • İlter Özer Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Gastroenterological Surgery
  • Bülent Ünal Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Surgical Oncology, Eskişehir
  • Murat Ulaş Eskişehir Osmangazi University Faculty of Medicine, Department of General Surgery, Section of Gastroenterological Surgery

Keywords:

peritoneal carcinomatosis, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy

Abstract

Purpose: Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy is an important treatment option in patients with primary diagnosis of colorectal cancer, ovarian cancer, appendix cancer, gastric cancer (selected cases), malignant peritoneal mesothelioma and peritoneal pseudomyxoma in the presence of peritoneal involvement and resectable lesions limited to the abdomen. In this study, it is aimed to discuss cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy(HIPEC) in the light of literature.

Patients and methods:

The data of patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy between June 2017 and September 2020 at Eskişehir Osmangazi University Medical Faculty Surgical Oncology and Gastroenterology Surgery Departments were analyzed. The study was designed retrospectively, and all patients who were discussed at the oncology council and decided on CRS + HIPEC were included in the study.

Results: 31 patients were included in the study. Primary diagnoses of the patients were colorectal cancer in 15 (48%), ovarian cancer in 9 (29%), stomach cancer in 3 (10%), mesothelioma in 2 (7%), appendix cancer in 1 (3%), and also peritoneal pseudomyxoma in 1 (3%). Therapeutic HIPEC was performed in 30 patients, prophylactic HIPEC was performed in 1 patient. Cytoreduction score was 0 in all patients. The median peritoneal cancer index was 15 (7-29). the median number of resected organs was 3(1-6). Stoma formation was performed in 14 patients (45%). During the postoperative 30 days, mortality was observed in 1 patient (3%) and morbidity in 5 patients (16%).

Conclusion: The early postoperative mortality and morbidity results which were reported in our study are compatible to those in the literature.

Published

2021-09-27

How to Cite

1.
Özdemir Ümit, Karayiğit A, Özdemir DB, Karakaya İhsan B, Dizen H, Özer İlter, Ünal B, Ulaş M. Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery; Experience and Short Term Outcomes. Arch Curr Med Res [Internet]. 2021Sep.27 [cited 2021Oct.28];2(3):168-76. Available from: https://acmronline.org/index.php/acmronline/article/view/64